OCT4 and SOX2 as Predictive Biomarkers for Radiotherapy Efficacy among Cervical Cancer Patients of North Indian Population
Archives of Advances in Biosciences,
Vol. 16 No. 1 (2025),
2 March 2025
,
Page 1-15
https://doi.org/10.22037/aab.v16i1.46817
Abstract
Introduction: Cervical cancer is a leading cause of mortality among women, largely influenced by clinical and histopathological tumor characteristics at diagnosis. While tumor size is an effective predictor of chemoradiotherapy (CRT) response, variability in treatment outcomes highlights the need for reliable biomarkers. OCT4 and SOX2, key stem cell markers, have been linked to cancer progression, poor prognosis, and chemoresistance. This study aims to evaluate the expression of OCT4 and SOX2 in cervical cancer tissues and assess their potential as predictive biomarkers for radiotherapy efficacy.
Materials and Methods: The study included 56 cervical cancer patients, with detailed data on cancer stage, tumor characteristics, and treatment modalities collected from medical records. Tissue microarrays were constructed from paraffin-embedded samples, and immunohistochemical staining was performed to assess OCT4 and SOX2 expression, with staining intensity analyzed using specialized software. Histoscores were compared across subgroups, and ROC analysis determined cut-off values for biomarker expression. Kaplan-Meier survival analysis, Cox regression, and chi-square tests were used to evaluate associations between biomarker expression, survival, and disease characteristics, with statistical significance set at p < 0.05.
Results: The study found that 66.1% of cervical cancer patients achieved a complete response to radiotherapy, while 33.9% had a partial response. Higher SOX2 and OCT4 expression levels were significantly associated with partial response and some toxicities like diarrhea. SOX2 showed stronger predictive value for radiotherapy response compared to OCT4, with significant differences in expression between complete and partial response groups. ROC analysis highlighted SOX2 as a more reliable biomarker for predicting treatment outcomes.
Conclusion: Higher expression of SOX2 and OCT4 was significantly associated with partial response to radiotherapy in cervical cancer patients, with SOX2 showing a stronger predictive value. These biomarkers may serve as useful tools for predicting radiotherapy efficacy and guiding personalized treatment strategies.
- Cervical cancer
- OCT4
- SOX2
- Predictive biomarkers
- Radiotherapy efficacy
- Immunohistochemistry
- Tissue microarray
- Biomarker expression
How to Cite
References
[1] Yim EK, Park JS. Biomarkers in cervical cancer. Biomark Insights. 2006;1:215-25. [DOI: 10.1177/117727190600100015] [PMID]
[2] Papadatou K, Perros P, Thomakos N, Haidopoulos D, Rodolakis A, Pergialiotis V. Biomarkers in cervical cancer. Hellenic J Obstet Gynecol. 2022;21(1):1-14. [DOI: 10.33574/hjog.0401]
[3] Yim EK, Park JS. Biomarkers in cervical cancer. Biomark Insights. 2006;1:215-25. [DOI: 10.1177/117727190600100015] [PMID]
[4] Bhatla N, Lal N, Bao YP, Ng T, Qiao YL. A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine. 2008;26(23):2811-7. [DOI: 10.1016/j.vaccine.2008.03.047] [PMID]
[5] Liu SC, Huang EY, Hu CF, Ou YC, ChangChien CC, Wang CJ, et al. Pretreatment factors associated with recurrence for patients with cervical cancer International Federation of Gynecology and Obstetrics stage IB1 disease. Gynecol Obstet Invest. 2016;81(4):339-45. [DOI: 10.1159/000441784] [PMID]
[6] Rodriguez NM. Participatory innovation for human papillomavirus screening to accelerate the elimination of cervical cancer. Lancet Glob Health. 2021;9(5):e582-3. [DOI: 10.1016/S2214-109X(20)30522-2] [PMID]
[7] Zhou J, Lei N, Tian W, Guo R, Chen M, Qiu L, et al. Recent progress of the tumor microenvironmental metabolism in cervical cancer radioresistance. Front Oncol. 2022;12:999643. [DOI: 10.3389/fonc.2022.999643] [PMID]
[8] Yang J, Cai H, Xiao ZX, Wang H, Yang P. Effect of radiotherapy on the survival of cervical cancer patients: an analysis based on SEER database. Medicine (Baltimore). 2019;98(30):e16421. [DOI: 10.1097/MD.0000000000016421] [PMID]
[9] Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005;25(14):6031-46. [DOI: 10.1128/MCB.25.14.6031-6046.2005] [PMID]
[10] Nishimoto M, Fukushima A, Okuda A, Muramatsu M. The gene for the embryonic stem cell coactivator UTF1 carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2. Mol Cell Biol. 1999;19(8):5453-65. [DOI: 10.1128/MCB.19.8.5453] [PMID]
[11] Okumura-Nakanishi S, Saito M, Niwa H, Ishikawa F. Oct-3/4 and Sox2 regulate Oct-3/4 gene in embryonic stem cells. J Biol Chem. 2005;280(7):5307-17. [DOI: 10.1074/jbc.M410015200] [PMID]
[12] Yuan H, Corbi N, Basilico C, Dailey L. Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev. 1995;9(21):2635-45. [DOI: 10.1101/gad.9.21.2635] [PMID]
[13] Schöler HR, Ruppert S, Suzuki N, Chowdhury K, Gruss P. New type of POU domain in germ line-specific protein Oct-4. Nature. 1990;344(6265):435-9. [DOI: 10.1038/344435a0] [PMID]
[14] Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65(13):5506-11. [DOI: 10.1158/0008-5472.CAN-05-0626] [PMID]
[15] Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70(24):10433-44. [DOI: 10.1158/0008-5472.CAN-10-2638] [PMID]
[16] Organista-Nava J, Gómez-Gómez Y, Gariglio P. Embryonic stem cell-specific signature in cervical cancer. Tumour Biol. 2014;35(3):1727-38. [DOI: 10.1007/s13277-013-1321-y] [PMID]
[17] Li X, Wang J, Xu Z, Ahmad A, Li E, Wang Y, et al. Expression of Sox2 and Oct4 and their clinical significance in human non-small-cell lung cancer. Int J Mol Sci. 2012;13(6):7663-75. [DOI: 10.3390/ijms13067663] [PMID]
[18] Paul SB, Tiwary BK, Choudhury AP. Studies on the epidemiology of cervical cancer in Southern Assam. Assam Univ J Sci Technol. 2011;7(1):36-42. [LINK]
[19] Shanthala S, Agadi BS, Kulkarni BB, Patil BR, Hallikeri UR, Chowkimath SM, et al. Snap shot of epidemiological pattern of cervical cancer patients reporting to a tertiary cancer care center in North Karnataka, India. Int J Adv Biol Res. 2014;4(2):178-83. [LINK]
[20] Spartacus RK, Paliwal R, Gaur P, Mutha S, Bhatt PR, Malavat A. A profile of cervical cancer cases in a government medical college hospital. IOSR J Dent Med Sci. 2015;14(10):37-42. [LINK]
[21] Yumkhaibam SD, Ramalingam M, Singh IY, Singh TT, Singh LJ, Daru HK, et al. Clinicoepidemiological study of cervical carcinoma in Northeast India. Indian J Appl Res. 2016;6(8):64-6. [LINK]
[22] Wadhwani R, Bamnia R, Meena M. Clinico-pathological analysis of cancer cervix in tertiary care centre. J Evol Med Dent Sci. 2013;2(39):7381-6. [LINK]
[23] Kaverappa VB, Prakash B, Kulkarni P, Renuka M. Sociodemographic profile of patients with cervical cancer in a tertiary-care cancer hospital in Mysuru, Karnataka. Int J Med Sci Public Health. 2015;4(9):1187-90. [DOI: 10.5455/ijmsph.2015.31032015239]
[24] Singh R, Shetty N, Naveed M, Pawar S, Iska S, Alugubelli NR. Retrospective analysis of patients with carcinoma cervix in a rural/semi-urban setting in Western India. Indian J Med Paediatr Oncol. 2016;37(1):25-7. [DOI: 10.4103/0971-5851.177011] [PMID]
[25] Akhtar PS, Hossain MM, Masud ZM, Ruksana N, Nahar S, Nahar L, et al. A comparative study of result of treatment of cancer cervix patients treated by two separate schedules of radiotherapy. Bangladesh J Obstet Gynaecol. 2010;25(2):50-8. [DOI: 10.3329/bjog.v25i2.13739]
[26] Narayana Swamy M, Gomathy E, Patil S, Seema BR. The scenario of cervical cancer in a rural medical college hospital. Int J Pharm Biomed Res. 2012;3(1):1-4. [LINK]
[27] Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012;11:73. [DOI; 10.1186/1476-4598-11-73] [PMID]
[28] Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem. 2005;280(26):24731-7. [DOI: 10.1074/jbc.M502573200] [PMID]
[29] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. [DOI: 10.1016/j.cell.2006.07.024] [PMID]
[30] Wen J, Park JY, Park KH, Chung HW, Bang S, Park SW, et al. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas. 2010;39(5):622-6. [DOI: 10.1097/MPA.0b013e3181c75f5e] [PMID]
[31] Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, et al. Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther. 2010;9(4):295-302. [DOI: 10.4161/cbt.9.4.10666] [PMID]
[32] Sowmya KR, Puranik MP, Aparna KS. Association between mother's behaviour, oral health literacy and children's oral health outcomes: a cross-sectional study. Indian J Dent Res. 2021;32(2):147-52. [DOI: 10.4103/ijdr.IJDR_676_18] [PMID]
[33] Wadhwani R, Bapat R, Shinde S, Shetty O. Cancer stem cell markers SOX2 and OCT4 predict prognosis in oral squamous cell carcinoma: an immunohistochemical study. Indian J Cancer. 2019;56(2):138-44. [LINK]
[34] Ameen NS, Johnstone A, Linton A, Murdoch L, Watkinson A. SOX2 as a therapeutic target in chemoresistant ovarian cancer. J Clin Oncol. 2019;37(15 Suppl):e15015. [LINK]
[35] Sabzghabaee AM, Mirmoghtadaee P, Mohammadi M. Fruit and vegetable consumption among community dwelling elderly in an Iranian population. Int J Prev Med. 2010;1(2):98-102. [PMID]
- Abstract Viewed: 327 times
- PDF Downloaded: 7 times